Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Follow-Up Questions
Quel est le ratio P/E de Champions Oncology Inc (CSBR) ?
Le ratio P/E de Champions Oncology Inc est de 19.0944
Qui est le CEO de Champions Oncology Inc ?
Mr. Robert Brainin est le Chief Executive Officer de Champions Oncology Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action CSBR ?
Le prix actuel de CSBR est de $6.81, il a increased de 0.82% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Champions Oncology Inc ?
Champions Oncology Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Champions Oncology Inc ?
La capitalisation boursière actuelle de Champions Oncology Inc est de $93.9M
Est-ce que Champions Oncology Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Champions Oncology Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte